Collaboration in Vaccine Development Announced

Artes Biotechnology and Bio Farma announced today to join forces for the development and manufacturing of vaccine candidates. The agreed collaboration involved the strength of both partners. Artes is specialised in cell line and process development, VLP based vaccines as well as in technology transfer for pharmaceutically relevant production processes whereas Bio Farma is involved in the manufacturing of vaccines, serum and other biological products for the Indonesian domestic and international markets.

“We are extremely delighted about the mutually agreed collaboration. Bio Farma is a strong and reliable pharmaceutical partner and the only vaccine and antisera producer for humans in Indonesia. We are more than confident, that we along with Bio Farma will develop vaccines highly relevant for the Indonesian and neighbouring markets. We expect that especially developments based on our Metavax® technology will contribute to Bio Farma´s vaccine portfolio”, Dr Michael Piontek, Founder and MD of Artes Biotechnology.

Metavax®  is a patent protected VLP technology, based on modifications to duck hepatitis B virus. The approach elicits a highly potent immune response and therefore a broader protection than the currently available VLP approaches. Artes´ Metavax® platform is suitable for the development and production of safe and cost-effective vaccines.